Thomas McCarthy Ph.D

Thomas McCarthy Ph.D General Information

Biography

Dr. Thomas McCarthy is the Founder and serves as Director & Co- Chief Executive Officer at M2M. He is a Co-Founder and serves as Executive Chairman at ThirtyFiveBio.He also is a Co-Founder and serves as Executive Chairman at GreyWolf Therapeutics. He serves as Chairman at Orbit Discovery. He is also a Co-Founder and serves as Executive Chairman at Pathios Therapeutics. He serves as Venture Partner at Brandon Capital Partners. He served as the Chief Executive Officer, Managing Director, President & Board Member at Spinifex Pharmaceuticals. He has over 16 years of experience in drug discovery and development and has been responsible for a variety of drug development programs under Investigation New Drug applications (IND) with the United States Food and Drug Administration (FDA) and other regulatory authorities. In addition to his role as CEO, he also oversees the CMC program for EMA401 and, with Alan Naylor (Spinifex SAB member), directs the AT2 receptor antagonist medicinal chemistry program. His prior positions include Vice President, Drug Development at Starpharma Pty Ltd where he was responsible for Starpharma's projects from lead candidate optimization/selection through to IND submission and clinical trials. In this role, he managed the development of SPL7013 Gel (VivaGel™) and was responsible for securing in excess of US$25M of United States National Institutes of Health (NIH) funding for Starpharma's drug development programs. He holds a Bachelor of Science (Hons) and PhD degrees from Monash University, Australia and completed his postdoctoral training at The University of Oxford.